Printer Friendly

SMITHKLINE BEECHAM AND YALE UNIVERSITY ANNOUNCE AGREEMENT ON LYME DISEASE VETERINARY VACCINE

 PHILADELPHIA, June 1 /PRNewswire/ -- SmithKline Beecham Animal Health (SB) and Yale University today announced an agreement on the development of a veterinary vaccine against Lyme disease.
 Under the agreement, SmithKline Beecham Animal Health has acquired a worldwide exclusive license to Yale patents relating to Lyme disease. The agreement provides the company the use of technology developed by Yale, which will allow SB to develop a vaccine to prevent Lyme disease in dogs and other animals.
 The efforts by SB to develop a vaccine will be enhanced by working in conjunction with the current human Lyme disease development program resulting from a collaboration between SmithKline Beecham and Yale, announced last year.
 "This agreement is a significant step forward in our strategy of leadership in the veterinary vaccine market in the U.S. and worldwide," said Ignace R. Goethals, president, SmithKline Beecham Animal Health. "By providing a vaccine against Lyme disease for animals, we can help both the pet and the pet owner avoid the debilitating effects of Lyme disease."
 Under the agreement, SB will pay license fees to Yale, as well as royalty payments once the vaccine is marketed.
 Since 1975, Yale medical faculty physicians and scientists have conducted significant research on Lyme disease. The Yale work being licensed derives from research performed by an interdisciplinary team including Stephen W. Barthold, D.V.M., Ph.D., Professor of Comparative Medicine; Erol Fikrig, M.D., Assistant Professor of Medicine (rheumatology); Richard A. Flavell, Ph.D., Professor and Chairman of Immunobiology at Yale and a Howard Hughes Medical Institute investigator; and Fred S. Kantor, M.D., the Paul B. Beeson Professor of Medicine.
 Barthold and his colleagues were the first to develop a laboratory model for Lyme disease using rats and mice; this model enables scientists to understand the disease so that better means of treatment, diagnosis and prevention, such as vaccines, can be developed for humans and animals.
 Lyme disease is named for the Connecticut town where Yale rheumatologists, Dr. Stephen E. Malawista, professor of Medicine, and Dr. Allen C. Steere, now at Tufts University, identified the first cluster of patients in 1975. The disease is usually caused when the bite of a tiny deer tick transmits a spiral-shaped bacterium, or spirochete, called Borrelia burgdorferi. Left untreated, the disease can cause a wide variety of symptoms in humans and animals. Dogs with Lyme disease can develop fever, lameness, heart disease and other disorders similar to humans.
 SmithKline Beecham Animal Health researches, develops, manufactures, markets and supports high-quality animal health care products for livestock and companion animals worldwide. The company is part of SmithKline Beecham (NYSE: SBH), one of the world's leading healthcare companies.
 SmithKline Beecham Animal Health is a leader in veterinary vaccines, and has pioneered such breakthrough biologicals as Leukocell, the first vaccine against feline leukemia; Primucell FIP, the first vaccine against feline infectious peritonitis; and PR-Vac, the first swine pseudorabies vaccine.
 /delval/
 -0- 6/1/93
 /CONTACT: Sharyn Arnold of SmithKline Beecham, 215-751-7074, or Helaine Patterson of Yale University School of Medicine, 203-785-5824/
 (SBH)


CO: SmithKline Beecham ST: Pennsylvania IN: MTC SU: JVN PDT

MP -- PH009 -- 3835 06/01/93 10:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 1, 1993
Words:523
Previous Article:PROGRESS FINANCIAL CORPORATION ANNOUNCES SUCCESSFUL CONSUMMATION OF STOCK OFFERING AND REGULATORY APPROVAL OF BRANCH ACQUISITION
Next Article:CABOT MEDICAL ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND DECLARES STOCK DIVIDEND
Topics:


Related Articles
SMITHKLINE BEECHAM AND YALE UNIVERSITY ANNOUNCE AGREEMENT ON LYME DISEASE VACCINE
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
RIBI IMMUNOCHEM EXPANDS COMMERCIAL RELATIONSHIP WITH SMITHKLINE BEECHAM BY PROVIDING ADJUVANTS FOR IMPORTANT GROUP OF BACTERIAL VACCINES
RIBI IMMUNOCHEM RESEARCH: MPL IMPROVES HEPATITIS B VACCINE PROTECTION IN ADVANCED HUMAN CLINICAL STUDIES
NEW LYME DISEASE VACCINE FOR DOGS OFFERS BROADER COVERAGE
SmithKline Beecham Completes Trial of Vaccine Against Lyme Disease; License Application To Be Filed; Placebo-Treated Patients To Be Vaccinated
First Lyme Disease Vaccine LYMErix(TM) Approved by FDA; SmithKline Beecham to Make New Vaccine Available Shortly.
Data Show LYMErix(R) Is Well Tolerated in Children and Is Effective Against Asymptomatic Infection in Adults.
[2] Data Show LYMErix(R) Is Well Tolerated in Children and Is Effective Against Asymptomatic Infection in Adults.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters